Caxton Associates (New York)
LYEL icon

Caxton Associates (New York)’s Lyell Immunopharma LYEL Stock Holding History

Caxton Associates (New York)’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,733
Closed -$389K – 546
2024
Q1 		$389K Buy
8,733
+6,831
+359% +$293K 0.02% 351
2023
Q4 		$73.8K Sell
1,902
-8,022
-81% -$289K ﹤0.01% 449
2023
Q3 		$292K Buy
9,924
+7,703
+347% +$366K 0.04% 312
2023
Q2 		$141K Buy
+2,221
New +$123K 0.02% 434

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (New York)'s LYEL Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 8,733 shares — an estimated $389K sold.

Caxton Associates (New York) first reported a position in LYEL in Q2 2023 and held it in 4 quarters. The position peaked at $389K in Q1 2024. 120 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 8,733 Lyell Immunopharma shares in Q2 2024, an estimated $389K.
  • Caxton Associates (New York) first reported a position in Lyell Immunopharma in Q2 2023 and held it in 4 quarters.
  • Caxton Associates (New York)'s Lyell Immunopharma position peaked at $389K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.